AnaptysBio Inc
NASDAQ:ANAB

Watchlist Manager
AnaptysBio Inc Logo
AnaptysBio Inc
NASDAQ:ANAB
Watchlist
Price: 23.47 USD -2.61% Market Closed
Market Cap: 714.2m USD
Have any thoughts about
AnaptysBio Inc?
Write Note

AnaptysBio Inc
Research & Development

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

AnaptysBio Inc
Research & Development Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Research & Development CAGR 3Y CAGR 5Y CAGR 10Y
AnaptysBio Inc
NASDAQ:ANAB
Research & Development
-$154.8m
CAGR 3-Years
-18%
CAGR 5-Years
-11%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Research & Development
-$7.9B
CAGR 3-Years
-4%
CAGR 5-Years
-9%
CAGR 10-Years
-10%
Gilead Sciences Inc
NASDAQ:GILD
Research & Development
-$5.5B
CAGR 3-Years
-4%
CAGR 5-Years
10%
CAGR 10-Years
-9%
Amgen Inc
NASDAQ:AMGN
Research & Development
-$5.8B
CAGR 3-Years
-7%
CAGR 5-Years
-8%
CAGR 10-Years
-3%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Research & Development
-$3.5B
CAGR 3-Years
-7%
CAGR 5-Years
-15%
CAGR 10-Years
-14%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Research & Development
-$4.9B
CAGR 3-Years
-20%
CAGR 5-Years
-14%
CAGR 10-Years
-15%
No Stocks Found

AnaptysBio Inc
Glance View

Market Cap
714.2m USD
Industry
Biotechnology

AnaptysBio, Inc. is a clinical stage biotechnology company. The company is headquartered in San Diego, California and currently employs 102 full-time employees. The company went IPO on 2017-01-26. The firm is focused on the immune control mechanisms applicable to inflammation and immuno-oncology indications. The company develops products using antibody discovery technology platform, which is based upon a natural process of antibody generation, known as somatic hypermutation, and replicates this natural process of antibody generation in vitro. Its advanced antibody programs include: Imsidolimab is an antibody that inhibits the interleukin-36 receptor, for the treatment of inflammatory diseases called generalized pustular psoriasis and hidradenitis suppurativa; Rosnilimab is an anti-PD-1 agonist antibody program, is designed to augment PD-1 signaling through Rosnilimab treatment to suppress T-cell driven human inflammatory diseases; anti-BTLA modulator antibody, known as ANB032, is applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation.

ANAB Intrinsic Value
18.32 USD
Overvaluation 22%
Intrinsic Value
Price

See Also

What is AnaptysBio Inc's Research & Development?
Research & Development
-154.8m USD

Based on the financial report for Sep 30, 2024, AnaptysBio Inc's Research & Development amounts to -154.8m USD.

What is AnaptysBio Inc's Research & Development growth rate?
Research & Development CAGR 5Y
-11%

Over the last year, the Research & Development growth was -27%. The average annual Research & Development growth rates for AnaptysBio Inc have been -18% over the past three years , -11% over the past five years .

Back to Top